Azilsartan medoxomil

Azilsartan is sometimes offered for kidney protection in chronic kidney disease, borrowing the reputation of the class. Renal outcomes were tested in randomised trials for losartan and irbesartan in diabetic nephropathy, where reduced proteinuria and slower loss of filtration held up. Azilsartan has no such trial, the AEMPS Edarbi label carries no renal indication, and experience in severe renal impairment is limited. At the same time the molecule raises potassium and can lower filtration in the first weeks, and reduced kidney function makes both effects stronger. When a sartan is needed for the kidneys specifically, the class holds drugs with direct data. If azilsartan was prescribed as a kidney protector, consider seeking a second opinion.

ICD-10: N18 · ICD-11: GB61

Sartans belong in heart failure regimens with reduced ejection fraction, but not all of them: the evidence sits with candesartan, valsartan and losartan, and European guidelines name those molecules. Azilsartan took part in no heart failure trial, and the AEMPS Edarbi label keeps the indication at essential hypertension. Swapping candesartan for azilsartan inside a heart failure regimen looks like a like-for-like change, yet nothing supports it, and the difference in dosing and in receptor binding makes the dose transfer far from obvious. Separately: heart failure regimens usually already carry spironolactone or eplerenone, and adding a sartan raises potassium more sharply than in someone with hypertension alone. If azilsartan was prescribed to treat heart failure, consider seeking a second opinion.

ICD-10: I50 · ICD-11: BD10